149 related articles for article (PubMed ID: 38451492)
1. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
[TBL] [Abstract][Full Text] [Related]
2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
3. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
4. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
5. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
6. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
Shore ND; Sutton J
Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
[TBL] [Abstract][Full Text] [Related]
7. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
8. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
[TBL] [Abstract][Full Text] [Related]
9. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R; Saad F; George DJ; Tombal B; Bailen JL; Cookson MS; Saltzstein DR; Hanson S; Brown B; Lu S; Fallick M; Shore ND
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38143206
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
[TBL] [Abstract][Full Text] [Related]
13. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
16. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
17. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
18. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
Adekunle OA; Seoane-Vazquez E; Brown LM
J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
[TBL] [Abstract][Full Text] [Related]
20. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
